Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilomilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 19/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 19/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilomilast SCHEMBL27516 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL13777301 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL26372 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL5975855 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL6904030 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL29107422 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130621 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130626 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7124080 | 0.97 | PDE4B (0.94) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL28381093 | 0.96 | PDE4B (0.92) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118541360-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2024-08-23 | — | — | CN | claimed |
| CN-117295717-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-12-26 | — | — | CN | claimed |
| EP-3359152-B1 | USE OF PDE4 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF DYSLIPOPROTEINAEMIA AND RELATED DISORDERS | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2020-05-27 | — | — | EP | claimed |
| EP-3165224-A1 | USE OF PDE4 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF DYSLIPOPROTEINAEMIA AND RELATED DISORDERS | Albert-Ludwigs-Universität Freiburg (DE) | 2017-05-10 | — | — | EP | claimed |
| EP-1305329-B2 | 6.ALPHA.,9.ALPHA.-DIFLUORO-17.ALPHA.-(2-FURANYLCARBOXYL)OXY-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT | GLAXO GROUP LTD (GB) | 2015-03-18 | — | — | EP | claimed |
| US-8273894-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-09-25 | — | — | US | claimed |
| US-20120190657-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-07-26 | — | — | US | claimed |
| US-7803760-B2 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2010-09-28 | — | — | US | claimed |
| US-20090226379-A1 | Bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethylpiperidin-4-yl ester; a beta 2 adrenergic receptor agonist; phosphodiesterase-4 inhibitor | THERAVANCE, INC. (US) | 2009-09-10 | — | — | US | claimed |
| WO-2009045397-A1 | METHODS FOR TREATING POLYCYSTIC KIDNEY DESEASE (PKD) OR OTHER CYST FORMING DISEASES | STOWERS INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-09 | — | — | WO | claimed |
| US-20030212112-A1 | Method for administering a phosphodiesterase 4 inhibitor | SMITHKLINE BEECHAM CORPORATION | 2003-11-13 | — | — | US | claimed |
| US-20030187006-A1 | Method for enhancing cognitive function | SMITHKLINE BEECHAM PLC (GB) | 2003-10-02 | — | — | US | claimed |
| US-20030171306-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2003-09-11 | — | — | US | claimed |
| EP-0919544-B1 | Compounds useful for treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORP (US) | 2003-05-14 | — | — | EP | claimed |
| EP-1289557-A2 | CANCER TREATMENT COMPOSITION CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| US-6369108-B1 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | claimed |
| WO-2001093909-A2 | CANCER TREATMENT COMPOSITION CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2001-12-13 | — | — | WO | claimed |
| EP-0633776-B1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2001-05-09 | — | — | EP | claimed |
| EP-0919544-A1 | Compounds useful for treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-02 | — | — | EP | claimed |
| US-5552438-A | Compounds useful for treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1996-09-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187006-A1 | Method for enhancing cognitive function | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
| US-20090226379-A1 | Bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethylpiperidin-4-yl ester; a beta 2 adrenergic receptor agonist; phosphodiesterase-4 inhibitor | ADRB1, ADRA1D, CHRM1 | PDE4B 15/4885PDE4A 19/4885PDE4C 29/4885 |
| US-20120190657-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | PDE4B 827/4885PDE4A 1337/4885PDE4C 1520/4885 |
| US-20030171306-A1 | Cancer treatment method | PDE4A, PDE4B, SMPD4 | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.